Previous
England U20
Guinea U20
1
1
FT
Game Details
Venezuela U20
Vanuatu U20
7
0
FT
Game Details
Mexico U20
Germany U20
0
0
LIVE 35'
Game Details
South Korea U20
Argentina U20
1
0
LIVE 36'
Game Details
Guangzhou Evergrande
Kashima Antlers
12:00 PM UTC
Leg 1
Game Details
Muangthong United
Kawasaki Frontale
12:30 PM UTC
Leg 1
Game Details
Jeju United
Urawa Red Diamonds
6:00 AM UTC May 24, 2017
Leg 1
Game Details
Next

Trending: Griezmann rates Man United move

Latest
Read

Transfer Rater: Bakayoko to Chelsea

Transfers
Read

Spurs stars wish Ajax good luck

The Toe Poke
Read

Adrian Mutu fails second drugs test

The Italian Olympic Committee (CONI) has announced Fiorentina forward Adrian Mutu has failed a drugs test for the second time in his career.

Mutu, 31, provided a sample following a Serie A game against Bari in January 10 and traces of the substance sibutramine were found.

Sibutramine is an appetite suppressant and was recently banned from use in the UK amid fears that the drug could increase the risk of heart attacks and strokes.

A statement on CONI's website read: "CONI announces that a positive test has been confirmed on Adrian Mutu with the presence of metabolics of sibutramine found in tests done by the FIGC on January 10 after the Serie A game between Fiorentina and Bari."

Reports in Italy claim Mutu could be facing a ban of between one and four years as he contemplates the second drugs-related controversy of his career.

In 2004, Mutu tested positive for cocaine and was sacked by Chelsea, as well as being suspended from football for seven months. He subsequently joined Juventus before moving on to Florence in 2006.

In July 2009 the Court of Arbitration for Sport ordered Mutu to pay Chelsea £14.6 million for breaching his contract by taking the illegal drug.

Comments

Use a Facebook account to add a comment, subject to Facebook's Terms of Service and Privacy Policy. Your Facebook name, photo & other personal information you make public on Facebook will appear with your comment, and may be used on ESPN's media platforms. Learn more.